Summa Corp. Has $232,000 Stake in Zoetis Inc. (NYSE:ZTS)

Summa Corp. raised its holdings in Zoetis Inc. (NYSE:ZTS) by 37.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,424 shares of the company’s stock after acquiring an additional 387 shares during the period. Summa Corp.’s holdings in Zoetis were worth $232,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Darwin Wealth Management LLC acquired a new position in shares of Zoetis during the third quarter worth about $31,000. First Personal Financial Services acquired a new position in shares of Zoetis during the third quarter worth about $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis during the third quarter worth about $33,000. Dunhill Financial LLC boosted its position in shares of Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after buying an additional 75 shares during the period. Finally, Quarry LP boosted its position in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after buying an additional 153 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Down 0.1 %

Shares of NYSE:ZTS opened at $170.33 on Thursday. The firm has a market cap of $76.85 billion, a P/E ratio of 32.02, a P/E/G ratio of 2.57 and a beta of 0.89. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53. The business has a fifty day simple moving average of $169.93 and a 200 day simple moving average of $179.65.

Zoetis (NYSE:ZTS) last announced its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period last year, the company earned $1.36 EPS. Zoetis’s revenue for the quarter was up 11.6% compared to the same quarter last year. Analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be paid a $0.50 dividend. The ex-dividend date is Tuesday, January 21st. This is an increase from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. Zoetis’s dividend payout ratio (DPR) is currently 37.59%.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ZTS. Stifel Nicolaus reduced their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. UBS Group assumed coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Finally, JPMorgan Chase & Co. increased their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $215.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.